Clinical Correlates of Benefit From Radium ‐223 Therapy in Metastatic Castration Resistant Prostate Cancer

CONCLUSIONSPatients earlier in their disease course with <5 BSI, low pain score, and good ECOG performance status are optimal candidates for radium‐223. Radium‐223 therapy is well tolerated with most patients reporting declines in pain scores and BSI. Prostate 9999: XX‐XX, 2016. © 2016 Wiley Periodicals, Inc.

Source: The Prostate - December 19, 2016 Category: Urology & Nephrology Authors: Ajjai Alva, Luke Nordquist, Stephanie Daignault, Saby George, Jorge Ramos, Costantine Albany, Sudhir Isharwal, Matthew McDonald, Gregory Campbell, Pongwut Danchaivijitr, Sarah Yentz, Aseem Anand, Evan Y. Yu Tags: Original Article Source Type: research